Partner, Northside Cardiology, P.C., a seven-person private practice group providing interventional and general cardiovascular consultative services at Northside Hospital-Sandy Springs, Northside Hospital-Forsyth, and St. Joseph’s Hospital in Atlanta, GA (9/5/2000-present).
Percutaneous Coronary and Peripheral Intervention
Complex Coronary and Cardiac Intervention
Peripheral and Craniocervical Arterial Angiography and Intervention
Radial Artery Access Diagnostic and Interventional Catheterization
Medical Director of Cardiology and Cardiac Rehabilitation Services, Northside Hospital, Atlanta, GA, 3/1/02- present, actively managing equipment, facilities, personnel and programs necessary to provide excellence in cardiovascular care and service at Northside Hospital.
Interventional Cardiology Fellow, Andreas Gruentzig Cardiovascular Center, Emory University Interventional Cardiology, Atlanta, GA. 7/1999-7/2000. Director of Interventional Cardiology: John S. Douglas, Jr. M.D., Emory University Cardiology, Suite 4C, 1365 Clifton Rd., NE, Atlanta, GA 30322
Clinical Cardiology Fellow, Emory University Cardiology, Atlanta, GA, 7/1997-7/1999.Fellowship Program Director: Robert W. Taylor, M.D., Ph.D., WMB 319, 1639 Pierce Dr., NE, Atlanta, GA 30322
Basic Science Molecular Cardiology Research Fellow, Emory University Cardiology, Atlanta, GA, 7/1994-7/1997. Endothelial Cell Gene Regulation Research: Ets and NF-kB redox-sensitive activation mechanisms . Fellowship Program Director: Robert W. Taylor, M.D., Ph.D., WMB 319, 1639 Pierce Dr., NE, Atlanta, GA 30322
Internship and Residency
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 1991-1994
Bronze Beeper Award for Student Teaching 1993-1994
University of North Carolina , Chapel Hill, NC, 1987-1991
American Heart Association, Council on Clinical Cardiology
American College of Physicians/Amer. Soc. of Internal Med., Member
American Board of Internal Medicine-Interventional Cardiology (11/8/00), Cardiology (11/3/99), and Internal Medicine (8/94).
Basic Life Support (Exp. 1/10/05)
Advanced Cardiac Life Support (Exp. 1/10/05)
L. Van-Thomas Crisco. Stable Angina Pectoris in The AHA Clinical Cardiac Consult, Joseph S. Alpert, MD. editor, Lippincott –Williams- Wilkins, 2000.
L. Van-Thomas Crisco and Douglas C. Morris. Interventional Cardiology Update, in Society for Cardiac Anesthesiologists Update 2000 Monograph, Jack Shanewise, MD, editor, Lippincott –Williams- Wilkins, 2001.
William S. Weintraub, Stephen D. Clements, Jr, L. Van-Thomas Crisco, Robert A. Guyton, Joseph M. Craver, Ellis L. Jones, and Charles R. Hatcher, Jr. Twenty-Year Survival After Coronary Artery Surgery: An Institutional Perspective From Emory University, Circulation 107: 1271-1277, 2003.
Thalidomide Fails to Inhibit Adventitial Angiogenesis and Restenosis in the Swine Model of Balloon Overstretch Injury. L. Van-Thomas Crisco, MD. Poster Presentation at the Keystone Symposium: Cellular and Molecular Regulation of Angiogenesis and Vasculogenesis, Salt Lake City, UT, March, 2000.
20-Year Survival After Coronary Artery Surgery: An Institutional Perspective From Emory University. L. Van-Thomas Crisco, MD Presented orally at the American Heart Association Scientific Sessions 72nd Annual Scientific Sessions, Atlanta, GA November 1999.
Endothelial cell Ets-dependent gene expression is redox-sensitive. L. Van-Thomas Crisco, MD Presented in poster format at the American Heart Association Conference on Structure and Function of the Vascular Wall, Santé Fe, NM February 1996.
NF-kB-dependent VCAM-1 promoter activation by TNF-a and linoleic acid is inhibited by PDTC via a redox-sensitive mechanism. Presented in poster format at the American Heart Association Conference on Structure and Function of the Vascular Wall, Snowbird, UT February 1995.
As Principal Investigator EVENT REGISTRY: A Multicenter Registry for the Evaluation of Drug Eluting Stents and Ischemic Events
Closure I: A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System versus Best Medical Therapy in Patients with a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through A Patent Foramen Ovale
ACRI Patient Registry: Medical Use of Anticoagulants in the Community Hospital Setting…a 5000 Patient Registry
As Sub-Investigator Deliver: A Prospective, Randomized, Single-Blinded, Parallel-Group (Two-Arm), Multi-Center, Clinical Evaluation of The RX Achieve™ Drug-Coated Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions - The Deliver Trial #01-345
ADEST: Protocol #TMC-BIV-03-02; Clinical Evaluation of the Concomitant use of Bivalirudin (Angiomax®) and a Drug-Eluting Stent
(Retired 6/24/04) Berlex: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5fgf-4 in Patients with Stable Angina; Berlex Protocol #304386
Research Experience As Sub-Investigator (cont) SIROLIMUS: An Evaluation of the Sirolomus-Coated BX Velocity™ Balloon-Expandable Stent in the Treatment of Patients with In-Stent Restenotic of Native Coronary Artery Lesions; Protocol #ACRI 01-01(Retired 4/28/05) The TheraP Trial: A Safety and Feasibility Study of the use of the TheraSource™ Intravascular Brachytherapy System for Prevention of Restenosis Following Successful Percutaneous Transluminal Angioplasty (PTA) in Superficial Femoral and Popliteal Arteries (Retired 4/20/05)
TAXUS V: De Novo Lesions; A Randomized, Double-Blind Trial to Assess TAXUS™ Paclitaxel-Eluting Coronary Stents, Slow-Release Formulation, in the Treatment of De Novo Coronary Lesions
SISR: A Multi-Center, Randomized, Study of the Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent vs. Intravascular Brachytherapy in the Treatment of Patients with In-Stent Restenotic Coronary Artery Lesions
MyoHeart: A Phase I, Open-Label, Non-Randomized, Dose Escalation, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous Skeletal Myoblast (Myocell™) Implantation by a Transendocardial Catheter Delivery System (MyoCath™) in Congestive Heart Failure Patients Post Mycardial Infarction(s) with Previous Placement of an Implantable Cardioverter Defibrillator (MYOHEART™)
Endeavor IV: A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus™ Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
TRANSCENDENCE-PCI: A Multicenter, Randomized, Double-Blind, Placebo
Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-